Group 1 - The core point of the article is that Heng Rui Medicine has received conditional approval from the National Medical Products Administration for its self-developed innovative drug, SHR2554 tablets, for adult patients with relapsed or refractory peripheral T-cell lymphoma who have previously undergone at least one line of systemic therapy [1] Group 2 - SHR2554 tablets are the first self-developed EZH2 inhibitor in China, representing a new, efficient, and selective oral EZH2 inhibitor [2] - The global sales of Tazverik, an EZH2 inhibitor developed by Epizyme, are projected to reach approximately $51 million in 2024 [2] - The cumulative R&D investment for SHR2554 tablets has reached approximately 213 million yuan [2]